| 1 |
Pitoia F. Response to sorafenib treatment in advanced metastatic thyroid cancer[J]. Arq Bras Endocrinol Metabol, 2014, 58(1): 37-41.
|
| 2 |
Capdevila J,Argiles G,Rodriguez-Frexinos V, et al. New ap-proaches in the management of radioiodine-refractory thyroid can-cer: the molecular targeted therapy era[J]. Discov Med, 2010, 9(45):153-162.
|
| 3 |
Thomas L,Lai SY,Dong W, et al. Sorafenib inmetastatic thyroid cancer: a systematic review[J]. Oncologist, 2014, 19(3): 251-258.
|
| 4 |
MacCorkle RA,Tan TH. Mitogen-activated protein kinases in cell-cycle control[J]. Cell BiochemBiophys, 2005, 43(3): 451-461.
|
| 5 |
Santoro M,Melillo RM,Fusco A. RET/PTC activation in papillary thyroidcarcinoma: European Journal of Endocrinology Prize Lec-ture[J]. Eur J Endocrinol, 2006, 155(5): 645-653.
|
| 6 |
Pak K,Suh S,Kim SJ, et al.Prognostic value of genetic mutations in thyroid cancer: a meta-analysis[J]. Thyroid, 2015, 25(1): 63-70.
|
| 7 |
Pelizzoa MR,Dobrinja C,CasalIdea E, et al. The role of BRAF(V600E) mutation as poor prognostic factor for the outcome of pa-tients with intrathyroid papillary thyroid carcinoma[J]. Biomed Pharmacotherapy, 2014, 68(4): 413-417.
|
| 8 |
石臣磊,秦华东.乳头状甲状腺癌与BRAF基因相关性的研究进展[J].中国普通外科杂志, 2014, 23(5): 675-679.
|
| 9 |
Yarchoan M,LiVolsi VA,Brose MS. BRAF mutation and thyroid cancer recurrence[J]. J Clin Oncol, 2015, 33(1): 7-8.
|
| 10 |
于洋,高明.甲状腺癌分子靶向治疗进展[J].中国肿瘤防治杂志, 2008, 15(8): 632-634.
|
| 11 |
Brose MS,Nutting CM,Jarzab B, et al. Sorafenib in radioactive io-dine-refractory, locally advanced or metastatic differentiated thy-roid cancer: a randomised, double-blind, phase 3 trial[J]. Lancet, 2014, 384(9940): 319-328.
|
| 12 |
Shen CT,Qui ZL,Luo QY. Sorafenib in the treatment of radioio-dine-refractory differentiated thyroid cancer: a meta-analysis[J]. Endocr Relat Cancer, 2014, 21(2): 253-261.
|
| 13 |
Marotta V,Ramundo V,Camera L, et al. Sorafenib in advanced io-dine-refractory differentiated thyroid cancer: efficacy, safety and exploratory analysis of role of serum thyroglobulin and FDG-PET[J]. ClinEndocrinol (Oxf), 2013, 78(5): 760-767.
|
| 14 |
Hoftijzer H,Heemstra KA,Morreau H, et al. Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma[J]. Eur J Endocri-nol, 2009, 161(6): 923-931.
|
| 15 |
Bellesoeur A,Carton E,Mir O, et al. Critical role Of sorafenib ex-posure over time for its antitumor activity in thyroid cancer[J]. In-vest New Drugs, 2014, 32(3): 569-572.
|
| 16 |
Boudou-Rouquette P,Ropert S,Mir O, et al. Variability of sorafenib toxicity and exposure over time: a pharmacokinetic/phar-macodynamic analysis[J]. Oncologist, 2012, 17(9): 1204-1212.
|
| 17 |
Brose MS,Nutting C,Shong YK, et al. Association between tumor BRAF and RAS mutation status and clinical outcomes in patients with radioactive iodine (RAI)-refractory differentiated thyroid can-cer (DTC) randomized to sorafenib or placebo: sub-analysis of the phase Ⅲ DECISION trial[C]. ECCO/ESMO/ESTRO Annual Meet-ing, Amsterdam, 2013.
|
| 18 |
Lam ET,Ringe MD,Kloos RT, et al. Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer[J]. J Clin Oncol, 2010, 28(14): 2323.
|
| 19 |
Capdevila J,Iglesias L,Halperin I, et al. Sorafenib in metastatic thyroid cancer[J]. Endocr Relat Cancer, 2012, 19(2): 209-216.
|
| 20 |
Savvides P,Nagaiah G,Lavertu P, et al. Phase II trial of sorafenib in patients with advanced anaplastic carcinoma of the thyroid[J]. Thyroid, 2013, 23(5): 600-604.
|
| 21 |
严丽,冀宏.索拉非尼对甲状腺未分化癌细胞增殖、迁移及侵袭能力的影响[J].中国医院药学杂志, 2014, 34(19): 1631-1634.
|
| 22 |
Mir O,Coriat R,Blanchet B, et al. Sarcopenia predicts early dose-limiting toxicities and pharmacokinetics of sorafenib in patients with hepatocellular carcinoma[J]. PLoS One, 2012, 7(5): e37563
|
| 23 |
Huillard O,Mir O,Peyromaure M, et al.Sarcopenia and body mass index predict sunitinib-induced early dose-limiting toxicities in renal cancer patients[J]. Br J Cancer, 2013, 108(5): 1034-1041.
|
| 24 |
Azad NS,Aragon-Ching JB,Dahut WL, et al. Hand-foot skin re-action increases with cumulative sorafenib dose and with combina-tion anti-vascular endothelial growth factor therapy[J]. Clin Can-cer Res, 2009, 15(4): 1411-1416.
|
| 25 |
Zhang L,Zhou Q,Ma L, et al. Meta-analysis of dermatological tox-icities associated with sorafenib[J]. Clin Exp Dermatol, 2011, 36(4): 344-350.
|
| 26 |
Ren Z,Zhu K,Kang H, et al. A randomized controlled phase II study of the prophylactic effect of urea-based cream on the hand-foot skin reaction associated with sorafenib in advanced hepatocel-lular carcinoma[C]. Annual Meeting of the American Society of Clinical Oncology, 2012, abstract no. 4008.
|
| 27 |
Dadu R,Waguespack SG,Sherman SI, et al. Efficacy and tolera-bility of different starting doses of sorafenib in patients with differ-entiated thyroid cancer[J]. Oncologist, 2014, 19(5): 477-482.
|
| 28 |
Ohba K,Takayama T,Matsunaga H, et al. Inappropriate elevation of serum thyrotropin levels in patients treated with axitinib[J]. Thy-roid, 2016, 23(4): 443-448.
|
| 29 |
Clemons J,Gao De,Naam M, et al. Thyroid dysfunction in patients treated with sunitinib or sorafenib[J]. Clin Genitourin Canc, 2012, 10(4): 225-231.
|
| 30 |
Je Y,Schutz FA,Choueiri TK. Risk of bleeding with vascular en-dothelial growth factor receptor tyrosine-kinaseInhibitors suni-tinib and sorafenib:a systematic review and meta-analysis of clini-cal trials[J]. Lancet Oncol, 2009, 10(10): 967-974.
|
| 31 |
Sherman EJ,Ho AL,Fury MG, et al. Phase II study of everolimus and sorafenib for the treatment of metastatic thyroid cancer[J]. J ClinOncol, 2013, 31(15suppl): 6024.
|